Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Type 2 diabetes mellitus diagnosed at least 1 year before the screening visit.~* Treatment with basal insulin for at least 6 months before the screening visit.~* Stable basal insulin regimen (i.e. type of insulin and time/frequency of the injection) for at least 3 months before the screening visit.~* Stable (plus/minus 20 percent) total daily basal insulin dose between 15 and 40 Units/day for at least 2 months prior to the screening visit.~* For participants receiving basal insulin and 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs could be 1 to 2 out of:~  * metformin (more than or equal to 1500 mg/day or maximal tolerated dose),~ * a sulfonylurea,~ * a glinide,~ * a dipeptidyl-peptidase-4 inhibitor,~ * a sodium glucose co-transporter 2 inhibitor,~* Fasting Plasma Glucose (FPG) less than or equal to 180 mg/dL(10.0 mmol/L) at screening visit for participants receiving basal insulin in combination with 2 OADs or with 1 OAD other than metformin; FPG less than or equal to 200 mg/dL (11.1 mmol/L) at screening visit for participants on basal insulin only or basal insulin plus metformin at screening visit.~* Signed written informed consent.~Exclusion criteria:~* Age under legal age of adulthood at screening visit.~* HbA1c at screening visit less than 7.5% or above 10%.~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Use of other oral or injectable glucose-lowering agents than stated in the inclusion criteria in a period of 3 months prior to screening.~* Previous use of insulin other than basal insulin eg, prandial or pre-mixed insulin, in the year prior to screening. Note: Short term treatment (≤10 days) due to intercurrent illness is allowed.~* History discontinuation of a previous treatment with Glucagon Like Peptide -1 Receptor Agonists for safety/tolerability or lack of efficacy.~* Participant who had previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide FRC or had previously received lixisenatide.~* Use of weight loss drugs within 3 months prior to screening visit.~* Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.~* History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).~* Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.~* At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m\^2.~* At screening visit amylase and/or lipase more than 3 times the upper limit of the normal (ULN) laboratory range.~* At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 3 ULN.~* At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).~* Any contraindication to metformin use, according to local labeling, if the participant was taking metformin.~* Participant who had a renal function impairment with creatinine clearance less than 30 mL/min (using the Cockcroft and Gault formula) or end-stage renal disease for participants, not treated with metformin.~Exclusion criteria for randomization:~* HbA1c less than 7% or above 10% .~* Mean fasting SMPG calculated from the self-measurements for 7 days the week before randomization visit was above 140 mg/dL (7.8 mmol/L).~* Average insulin glargine daily dose less than 20 Units or above 50 Units (in the week before randomization visit).~* Amylase and/or lipase more than 3 ULN .~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) (Type: EXPERIMENTAL): FRC once daily (QD) for 30 weeks. Dose individually adjusted.
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.

Based on this trial design, predict the completion outcome and termination type (if applicable).